Many individuals with cardiovascular disease (CVD) do not present with any of the disorder’s classic risk factors. Circulating proteins are a promising source for CVD biomarkers to complement existing clinically-relevant indicators. These proteins are often released at the very onset of CVD, well before visible manifestations or symptoms. However, detecting them at these low concentrations is a challenge.
Download this white paper from SomaLogic to learn how the SomaScan® assay overcomes obstacles linked with other assays, including insufficient detection sensitivity, non-specificity, and cross-reactivity.